LumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio

LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies bring products to the U.S. market. Building on the successful integration of AOXRE, LumiQuick is positioned to support oxidative stress research and specialty diagnostic technologies.

Beyond supplying products, the expanded offering includes original equipment manufacturer (OEM), private-label, and contract manufacturing services, along with strategic commercialization support for the United States. Together, these capabilities are designed to support partners from early development through market entry.

Image: Building on AOXRE’s integration, LumiQuick aims to advance oxidative stress research and specialty diagnostics through innovation, expanded manufacturing, and partnerships

The service scope spans product development, design transfer, manufacturing scale‑up, and product assembly and packaging. Operational capabilities include reagent dispensing and packaging and custom diagnostic solutions across lateral flow immunoassays, rapid diagnostic tests, and ELISA development and manufacturing. 

The company's expertise also includes recombinant proteins, antibodies, biomarker assays, and reagent formulation, providing a single‑source pathway from concept through commercialization. Regulatory services include U.S. Food and Drug Administration (FDA) 510(k) submission support.

LumiQuick is seeking collaborations with biotechnology companies, diagnostic developers, research organizations, and international manufacturers aiming to establish or expand their U.S. presence with an experienced commercial and manufacturing partner. The team will be available at the ADLM Clinical Lab Expo 2026, Booth #1156, to discuss the expanding AOXRE portfolio, new product innovations, OEM and private‑label options, contract manufacturing, FDA 510(k) support, and commercialization partnerships.

The initiative underscores a commitment to advancing oxidative stress research and specialty diagnostic technologies through continued product innovation, expanded manufacturing capabilities, and strategic industry partnerships.

“Our goal is to become more than a manufacturer,” said Talita Franco, Business Development & Marketing Director at LumiQuick Diagnostics. “We are committed to helping innovative companies transform scientific discoveries into commercially successful products by combining technical expertise, manufacturing excellence, regulatory guidance, and market development support.”